Cj Lee Email and Phone Number

Leading the Business Operations department by defining strategies, ensuring execution, and achieving of its business objectives. Be accountable for the optimization of commercial effectiveness and efficiency through equipping the required competencies of commercial team and identifying opportunities and risk with market insights.

Led new product launch preparations and to develop innovative solutions for launch challenges, and to actively manage uncertainties in order to maximize the value of all brands. Responsible for delivering and facilitating cross-functional alignment to a globally consistent launch framework and process for country launch planning and execution.Supporting senior management team to prepare LOC business planning and review e.g. MRP, MYC and LRF and leading various projects to enhance business operation efficiency. ▪ Guided the team to prepare business case for new launch products across diverse therapeutic areas including oncology, GI disease and rare disease etc. to get regional and HQ’s endorsement and support for launch. ▪ Led the cross-functional for launch preparation optimization and market sharping to make the new product launch successfully.

Led the marketing team for Hematology promotion and Oncology new products launch preparation in Taiwan. ▪ Guided the team to secure market leader position in Hodgkin Lymphoma and worked with RA team for new indications approval as well as Market Access team for reimbursement expansion. ▪ Managed new product commercial launch in Multiple Myeloma and conducted the BIA (Budget Impact Analysis) and MEA proposal independently for reimbursement application. ▪ Led the cross-functional team for new product launch preparation and KOLs management.

▪ Lead and manage the commercial team for Hematology (Revlimid®, Vidaza®and Pomalyst®) and Oncology (Abraxane®) portfolio and support the newtherapeutic area entry (I&I, Immune and Inflammation) for newproduct launch preparation in Taiwan.▪ Secure Revlimid® market leader position in Multiple Myeloma with 84%market share. Successfully extended the reimbursement cycles from 12 to18 cycles and hit the historical high record via conversion program.▪ Accelerated Pomalyst® launch readiness and hospital listing preparation tomaximize the business opportunities from advanced reimbursementapproval timeline.▪ Guided the commercial team to rebuild the business foundation during thetransition period and achieved Celgene Taiwan 2017 commitment (100%sales achievement with 6% growth vs. PY).

▪ Lead and manage the Renal Cell Carcinoma/ GastrointestinalTumours products portfolio (Sutent®, Inlyta® and Torisel®) and Lung Cancer(Xalkori®) in Taiwan and prepare Haematoloy new products launchreadiness. Directly report to the Regional Therapeutic Are Lead forEM-ASIA Oncology and actively interactive/involvement in regionalmarketing team operation.▪ Secure Sutent® market leader position with 80% market share and ~70%initiation in highly competitive market.▪ Conducted multidisciplinary integration in GIST and RCC promotion tofacilitate early switch and individualized treatment dosing schedule strategieswhich result 113% RCC portfolio 2016 sales achievement.▪ Honorable mentions in Pfizer PIH HERO AWARD in 2017 Year BeginningMeeting

▪Double the product penetration in target therapeutic area across entire sales territory.▪100+% achievement of aggressive sales growth target in highly competitive market▪Recruited external KOLs and internal stakeholders support to enable a critical IIT across 20+ cites.

▪Effectively achieved target product sales growth rate in saturated/highly-competitive market with limited resource▪Launched Roche brand as Oncology market leader through media campaign▪Initiated cross-sell in different therapeutic areas to expand product market size and maximize sales revenue.▪Proactively engaged KOLs to translate critical clinical science findings into high business impact medical society endorsement result in policy guideline change in a timely fashion to enable extensive market expansion opportunity.